KEWAUNEE SCIENTIFIC CORP /DE/
No SEC Form 4 filings for $KEQU in the last 30 days.
See all $KEQU insider activity →Kewaunee Scientific (KEQU) reported Q1 FY2027 results: sales $66.3M (-6.7% YoY), net earnings $1.7M (-34.7% YoY), EBITDA $4.5M (-34.7% YoY). Backlog grew to $169M. International segment earnings rose 23.5% despite lower sales. Long-term debt fell to $13.8M. CEO cited strong quoting activity and strategic execution.
KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Kewaunee Scientific Reports Results for First Quarter of Fiscal Year 2027 Exchange: NASDAQ (KEQU) Contact: Donald T. Gardner III 704/871-3274 STATESVILLE, N.C. September 9, 2026 – PRNewswire / Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its first qu
KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders On August 26, 2026, Kewaunee Scientific Corporation (the "Company") held its Annual Meeting of Shareholders (the "Annual Meeting"). At the Annual Meeting, the Company's shareholders voted on the matters set forth below
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning KEQU (KEWAUNEE SCIENTIFIC CORP /DE/). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent KEQU coverage spans insider activity, earnings and corporate actions.
Earnings miss and declining sales may pressure the stock, while improved backlog and lower debt provide some support.
Earnings miss may pressure the stock short term; backlog growth offers upside potential.
Routine governance filing with no material impact on valuation.
The announcement sets the date for the upcoming earnings release, providing a timing cue but no new financial data.
Routine insider sale to issuer (likely buyback participation) with no 10b5-1 plan disclosed; limited signal for fundamentals.
AlphAI scores every news story that mentions KEQU with an AI model for sentiment and relevance, and aggregates insider trades from KEWAUNEE SCIENTIFIC CORP /DE/'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kewaunee Scientific (KEQU) reported Q1 FY2027 results: sales $66.3M (-6.7% YoY), net earnings $1.7M (-34.7% YoY), EBITDA $4.5M (-34.7% YoY). Backlog grew to $169M. International segment earnings rose 23.5% despite lower sales. Long-term debt fell to $13.8M. CEO cited strong quoting activity and strategic execution.
2 min readKEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Kewaunee Scientific Reports Results for First Quarter of Fiscal Year 2027 Exchange: NASDAQ (KEQU) Contact: Donald T. Gardner III 704/871-3274 STATESVILLE, N.C. September 9, 2026 – PRNewswire / Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its first qu
2 min readKEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders On August 26, 2026, Kewaunee Scientific Corporation (the "Company") held its Annual Meeting of Shareholders (the "Annual Meeting"). At the Annual Meeting, the Company's shareholders voted on the matters set forth below
1 min readKewaunee Scientific (NASDAQ: KEQU) will release its Q1 fiscal 2027 results on September 9, 2026, after market close. The company designs and manufactures laboratory and healthcare furniture, with operations in the U.S. and internationally. It also includes forward-looking statements about risks and uncertainties.
1 min readPhillips Elizabeth D (SVP, People & Culture) sold (to issuer) 4,995 shares of KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) at $36.25 ($0.18M total) on 2026-06-30.
2 min readNoble Ryan S. (SVP, Sales & Marketing Dev) sold (to issuer) 3,000 shares of KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) at $36.25 ($0.11M total) on 2026-06-30.
1 min readBatdorff Douglas J. (SVP, Manufacturing Operations) sold (to issuer) 5,609 shares of KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) at $36.25 ($0.20M total) on 2026-06-30.
2 min readGardner Donald T. III (Chief Financial Officer) sold (to issuer) 12,000 shares of KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) at $36.25 ($0.44M total) on 2026-06-30.
2 min readHULL THOMAS DAVID III (President & CEO) sold (to issuer) 17,000 shares of KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) at $36.25 ($0.62M total) on 2026-06-30.
2 min readKEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 prfy26q4earningsrelease.htm EX-99.1 Document Kewaunee Scientific Reports Results for Fiscal Year and Fourth Quarter Exchange: NASDAQ (KEQU) Contact: Donald T. Gardner III 704/871-3274 STATESVILLE, N.C. June 23, 2026 – PRNewswire / Kewaunee Scientific Corporation (NASDAQ
4 min read
